Some of the recent NIA Approved Concepts for funding (see https://www.nia.nih.gov/approved-concepts#collaborative ) encourage the use of mouse models created by the MODEL-AD program. All of the models generated will be listed on the “Resources” section of this website, and will be available from JAX. Please contact us at ModelAD@iupui.edu if you would like us to provide a letter of support.
MONDAY, NOV. 13, 2017
Session 386 Alzheimer’s Disease: Genetics and Functional Genomic (1:00 – 5:00 PM)
Presentation 386.01 / V26 / 1:00-2:00
Model-ad: Genetic models of late-onset Alzheimer’s disease
Presentation 386.05 / W4 / 1:00-2:00
MODEL-AD: The disease modeling project
Presentation 386.02 / W1 / 2:00-3:00
Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy
Presentation 386.03 / W2 / 3:00-4:00
Novel candidate loci for Alzheimer’s disease from whole-genome and whole-exome sequencing
Presentation 386.04 / W3 / 4:00-5:00
Model-ad: Bioinformatics and data management core
We will be presenting our progress at the Alzheimer’s Association International Conference in London in July.
Monday July 17
Genetic Factors of Alzhemer’s Disease:
Cross Study Integrative Network Analysis Identification of AD Disease Etiology
Wednesday July 19
Basic and Translational Science: Development of New Models and Analysis Methods:
Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease: MODEL-AD
Wednesday July 19
Creating a Humanized Mouse Model of CR1 and CR2 to Better Model Alzheimer’s Disease Risk Factors
Wednesday July 19
Novel Candidate Loci for Late-Onset Alzheimer’s Disease from Bayesian Mixed Modeling of Whole-Genome and Whole-Exome Sequencing
The JAX MODEL-AD Center staff and friends participated in the The Longest Day to raise funds and awareness for the care, support and research efforts of the Alzheimer’s Association. We started the day with sunrise on the top of Cadillac Mountain, then hiked every peak in Acadia, paddled and swam in Long Pond, and ended the day with sunset at Pretty Marsh.
Together we raised more than $7,000 and spoke to many people throughout the day about the plight of Alzheimer’s patients and caregivers.
Thanks to all we participated and donated, and thanks to Adam Lacher of the Maine Chapter of the Alzheimer’s Association for joining us for lunch.
If you would like to donate, please go to our The Longest Day team page.
Transcriptomic data has been collected from left hemisphere of both WT and APP/PS1 mouse model. APP/PS1 double transgenic mice C57BL/6J.APPswePsen1de9 mice (herein referred to as B6.APBTg) were obtained from The Jackson Laboratory and maintained in 14/10-hour light/dark cycle. To generate experimental mice, B6.APBTg/+ mice were mated to C57BL/ 6 J (B6) mice to generate AD and wild-type (WT) cohorts. To minimize gene expression variation between mice, all mice in experimental cohorts were bred in the same mouse room, were aged together (to the extent possible) and only females were assessed. Mice from 2–12 months old were used in this study.
The Jackson Laboratory hosted a MODEL-AD Mini-Symposium on Monday, May 22, 2017 from 2:15 to 5:15 p.m in the LCC Auditorium at our Bar Harbor, Maine campus. The symposium included updates from Alzheimer’s Disease experts and was followed by a poster session. For more information, please contact Mike Sasner (email@example.com).
- 2:15 pm: Welcome – Gareth Howell, Ph.D., Associate Professor, The Jackson Laboratory
- 2:30 pm: “Unraveling the Role of TREM2 in Alzheimer’s Disease Pathogenesis” Bruce Lamb, Ph.D., Roberts Family Chair in Alzheimer’s Disease Research, Executive Director, Stark Neurosciences Research Institute, Indiana University School of Medicine
- 2:45 pm: “Research at the Toronto Dementia Research Alliance” – Barry Greenberg, Ph.D., Director of Strategy, Toronto Dementia Research Alliance, University Health Network, Toronto
- 3:00 pm: “Preclinical Development of a CNS-active, Isoform-selective, p38alpha MAPK Inhibitor for Alzheimer’s Disease” – Linda Van Eldik, Ph.D., Director, Alzheimer’s Disease Center, University of Kentucky, Co-Director, Kentucky Neuroscience Institute, Vernon Smith Endowed Chair in Alzheimer’s Research
- 3:15 pm: “Systems Genetics Analysis of Resilience to Alzheimer’s Disease” Catherine Kaczorowski, Ph.D., Assistant Professor, The Jackson Laboratory
- 3:30 pm: “Appropriate Use of Animal Models to Translate Aβ Lowering Effects of BACE1 Inhibition to the Clinic” – Dave McKinzie, Ph.D., Research Fellow & Head of In Vivo Pharmacology, Eli Lilly
- 3:45 pm: “MODEL-AD: Creating the Next Generation of Animal Models for Alzheimer’s Disease” – Greg Carter, Ph.D., Associate Professor, The Jackson Laboratory
- 4:00 pm: Collaborative Frameworks and Open Science: New Frontiers in Systems Biology” – Ben Logsdon, Ph.D., Senior Scientist, Sage Bionetworks
- 4:15 pm: Poster session with wine and cheese
- 5:15 pm: Adjourn
A newly created mouse model of Alzheimer’s disease will be available soon. This expresses the two strongest genetic risk factors for late-onset AD: the human APOE4 allele and a knock-in of the R47H allele into the mouse Trem2 locus.
This has not been fully characterized yet, we are aging cohorts to be phenotyped as of April 2017.
This model is now available to register interest; doing so will allow you to place your order as soon as possible, and will enable JAX to scale the distribution colony to meet the demand. This can be done from the strain data sheet.
The AlzForum recently published a story on the new MODEL-AD Center: